Abstract: . . .  as risk factors for venous thromboembolism: a matched case-control study. Lancet, 2002 Mar 2; 359 (9308): 747 -52. 21. Ifudu, O, Macey, LJ, Homel, P, Hyppolite, JC, Hong, J, Sumrani, N, Distant, D, Sonner, BG, Friedman, EA. Determinants of type of initial hemodialysis vascular access. Am J Nephrol, 1997 17(5): 425-427. Your questions, contributions and commentaries will be answered by the authors in the Clinical Cardiology list. Please fill in the form and press the "Send" button. Top Updating: 11/07/2003 Question, contribution or commentary : Name and Surname: : Country: : Argentina E-Mail address: @ Send Erase  . . .
. . .  the same period. Additional sub-group analyses included gender and age. Homocysteine (mcmol/L) was drawn each quarter (every 12 weeks) in all patients with ESRD during the 16 month period. Medical files revealed VAT with listed dates. Homocysteine and VAT were recorded and matched retrospectively during a sixteen (16) month period on both thrombosis prone and no thrombosis groups. All subjects recruited had a PTFE graft. No subjects were prescribed vitamin or mineral therapy during the course of the study. Statistical analysis included mean (SD) values for both thrombosis prone and no thrombosis groups for age (years) and total homocysteine (tHcy, mcmol/L). The Kolmogorov Smirnov test for normality was run for tHcy. A Mann-Whitney U non-parametric t-Test for variance between thrombosis prone and no thrombosis groups was performed for tHcy, VAT, and age. A chi-Square analysis between VAT and gender was performed. Spearman . . .
. . .  homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet, 2002 Mar 2; 359 (9308): 747 -52. 21. Ifudu, O, Macey, LJ, Homel, P, Hyppolite, JC, Hong, J, Sumrani, N, Distant, D, Sonner, BG, Friedman, EA. Determinants of type of initial hemodialysis vascular access. Am J Nephrol, 1997 17(5): 425-427. Your questions, contributions and commentaries will be answered by the authors in the Clinical Cardiology list. Please fill in the form and press the "Send" button. Top Updating: 11/07/2003 Question, contribution or commentary : Name and Surname: : Country: : Argentina E-Mail address: @ Send Erase  . . .
--3000,3,500,2791,20424